OTCMKTS:PKPH

Peak Pharmaceuticals Competitors

$0.13

0.00 (-1.44 %)

(As of 04/16/2021 08:10 PM ET)

Add

Compare

Today's Range

$0.12

Now: $0.13▼

$0.13

50-Day Range

$0.13

MA: $0.15▼

$0.20

52-Week Range

$0.01

Now: $0.13▼

$0.27

Volume174,400 shs

Average Volume427,649 shs

Market Capitalization$10.19 million

P/E RatioN/A

Dividend YieldN/A

Beta0.46

Peak Pharmaceuticals (OTCMKTS:PKPH) Vs. IIPR, GRWG, XXII, KSHB, NSAV, and TRTC

Should you be buying PKPH stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Peak Pharmaceuticals, including Innovative Industrial Properties (IIPR), GrowGeneration (GRWG), 22nd Century Group (XXII), KushCo (KSHB), NSAV (NSAV), and Terra Tech (TRTC).

Peak Pharmaceuticals vs. Innovative Industrial Properties Stock

Peak Pharmaceuticals (OTCMKTS:PKPH) and Innovative Industrial Properties (NYSE:IIPR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

74.9% of Innovative Industrial Properties shares are owned by institutional investors. 2.9% of Innovative Industrial Properties shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Peak Pharmaceuticals and Innovative Industrial Properties' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Innovative Industrial Properties	$44.67 million	97.38	$23.48 million	$3.27	55.60

Innovative Industrial Properties has higher revenue and earnings than Peak Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Peak Pharmaceuticals and Innovative Industrial Properties, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
Innovative Industrial Properties	0	2	5	0	2.71

Innovative Industrial Properties has a consensus target price of $192.4286, indicating a potential upside of 6.03%. Given Innovative Industrial Properties' higher possible upside, analysts clearly believe Innovative Industrial Properties is more favorable than Peak Pharmaceuticals.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Innovative Industrial Properties has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Profitability

This table compares Peak Pharmaceuticals and Innovative Industrial Properties' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	N/A
Innovative Industrial Properties	55.71%	6.05%	4.82%

Summary

Innovative Industrial Properties beats Peak Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals vs. GrowGeneration Stock

Peak Pharmaceuticals (OTCMKTS:PKPH) and GrowGeneration (NASDAQ:GRWG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Peak Pharmaceuticals and GrowGeneration's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	N/A
GrowGeneration	2.14%	4.68%	3.53%

Insider & Institutional Ownership

51.3% of GrowGeneration shares are held by institutional investors. 13.6% of GrowGeneration shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, GrowGeneration has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500.

Valuation & Earnings

This table compares Peak Pharmaceuticals and GrowGeneration's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GrowGeneration	$79 million	33.42	$1.88 million	$0.10	451.60

GrowGeneration has higher revenue and earnings than Peak Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and price targets for Peak Pharmaceuticals and GrowGeneration, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
GrowGeneration	0	3	5	0	2.63

GrowGeneration has a consensus price target of $49.5714, indicating a potential upside of 9.94%. Given GrowGeneration's higher possible upside, analysts clearly believe GrowGeneration is more favorable than Peak Pharmaceuticals.

Summary

GrowGeneration beats Peak Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals vs. 22nd Century Group Stock

Peak Pharmaceuticals (OTCMKTS:PKPH) and 22nd Century Group (NYSEAMERICAN:XXII) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Peak Pharmaceuticals and 22nd Century Group's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
22nd Century Group	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Peak Pharmaceuticals and 22nd Century Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
22nd Century Group	0	0	1	0	3.00

Profitability

This table compares Peak Pharmaceuticals and 22nd Century Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	N/A
22nd Century Group	N/A	N/A	N/A

Summary

22nd Century Group beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Peak Pharmaceuticals vs. KushCo Stock

KushCo (OTCMKTS:KSHB) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap multi-sector conglomerates companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Insider and Institutional Ownership

0.0% of KushCo shares are owned by institutional investors. 17.3% of KushCo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for KushCo and Peak Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KushCo	0	1	3	0	2.75
Peak Pharmaceuticals	0	0	0	0	N/A

KushCo currently has a consensus target price of $1.8750, indicating a potential upside of 58.90%. Given KushCo's higher probable upside, research analysts clearly believe KushCo is more favorable than Peak Pharmaceuticals.

Profitability

This table compares KushCo and Peak Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KushCo	-65.89%	-47.95%	-31.39%
Peak Pharmaceuticals	N/A	N/A	N/A

Valuation & Earnings

This table compares KushCo and Peak Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KushCo	$113.84 million	1.65	$-77,660,000.00	($0.68)	-1.74
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Peak Pharmaceuticals has lower revenue, but higher earnings than KushCo.

Risk & Volatility

KushCo has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Summary

KushCo beats Peak Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Peak Pharmaceuticals vs. NSAV Stock

Peak Pharmaceuticals (OTCMKTS:PKPH) and NSAV (OTCMKTS:NSAV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, NSAV has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500.

Valuation and Earnings

This table compares Peak Pharmaceuticals and NSAV's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NSAV	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Peak Pharmaceuticals and NSAV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	N/A
NSAV	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Peak Pharmaceuticals and NSAV, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
NSAV	0	0	0	0	N/A

Summary

NSAV beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Peak Pharmaceuticals vs. Terra Tech Stock

Peak Pharmaceuticals (OTCMKTS:PKPH) and Terra Tech (OTCMKTS:TRTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Peak Pharmaceuticals and Terra Tech's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Terra Tech	$28.05 million	2.15	$-46,930,000.00	N/A	N/A

Peak Pharmaceuticals has higher earnings, but lower revenue than Terra Tech.

Profitability

This table compares Peak Pharmaceuticals and Terra Tech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	N/A
Terra Tech	-261.88%	-110.38%	-62.41%

Analyst Ratings

This is a summary of current ratings and target prices for Peak Pharmaceuticals and Terra Tech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Pharmaceuticals	0	0	0	0	N/A
Terra Tech	0	0	0	0	N/A

Insider & Institutional Ownership

0.1% of Terra Tech shares are held by institutional investors. 6.7% of Terra Tech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Peak Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Terra Tech has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Summary

Terra Tech beats Peak Pharmaceuticals on 4 of the 7 factors compared between the two stocks.